Palvella Therapeutics (NASDAQ:PVLA) Stock Price Expected to Rise, Chardan Capital Analyst Says

Palvella Therapeutics (NASDAQ:PVLA) had its target price increased by Chardan Capital from $210.00 to $240.00 in a report released on Tuesday,Benzinga reports. The brokerage presently has a “buy” rating on the stock. Chardan Capital’s target price would suggest a potential upside of 92.54% from the company’s current price.

Several other equities research analysts have also weighed in on the stock. HC Wainwright increased their target price on shares of Palvella Therapeutics from $255.00 to $270.00 and gave the stock a “buy” rating in a report on Tuesday, March 24th. Truist Financial set a $210.00 price objective on shares of Palvella Therapeutics in a research report on Tuesday, February 24th. Raymond James Financial reaffirmed a “strong-buy” rating and set a $193.00 price objective on shares of Palvella Therapeutics in a research note on Tuesday, December 16th. Weiss Ratings reiterated a “sell (d)” rating on shares of Palvella Therapeutics in a report on Monday, December 29th. Finally, Canaccord Genuity Group boosted their target price on Palvella Therapeutics from $148.00 to $204.00 and gave the company a “buy” rating in a research note on Tuesday, December 16th. One investment analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $198.07.

Palvella Therapeutics Trading Up 12.6%

Shares of PVLA stock traded up $13.99 on Tuesday, reaching $124.65. The company had a trading volume of 548,620 shares, compared to its average volume of 315,123. The stock has a market cap of $1.48 billion, a PE ratio of -47.40 and a beta of -0.30. The company has a 50-day moving average of $104.74 and a 200-day moving average of $91.17. Palvella Therapeutics has a 12 month low of $18.23 and a 12 month high of $151.18.

Palvella Therapeutics (NASDAQ:PVLA) last released its quarterly earnings data on Tuesday, March 31st. The company reported ($1.08) earnings per share for the quarter, missing the consensus estimate of ($0.95) by ($0.13). Sell-side analysts anticipate that Palvella Therapeutics will post -3.69 earnings per share for the current year.

Insider Activity

In related news, Director George M. Jenkins acquired 4,000 shares of the company’s stock in a transaction that occurred on Friday, February 27th. The shares were acquired at an average cost of $125.00 per share, for a total transaction of $500,000.00. Following the completion of the acquisition, the director directly owned 187,171 shares in the company, valued at approximately $23,396,375. The trade was a 2.18% increase in their position. The purchase was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, COO Kathleen Goin sold 4,302 shares of the business’s stock in a transaction on Wednesday, March 18th. The shares were sold at an average price of $117.99, for a total transaction of $507,592.98. Additional details regarding this sale are available in the official SEC disclosure. Corporate insiders own 20.50% of the company’s stock.

Hedge Funds Weigh In On Palvella Therapeutics

A number of large investors have recently added to or reduced their stakes in PVLA. Group One Trading LLC grew its holdings in shares of Palvella Therapeutics by 151.5% in the 4th quarter. Group One Trading LLC now owns 332 shares of the company’s stock valued at $35,000 after acquiring an additional 200 shares in the last quarter. Archer Investment Corp bought a new stake in Palvella Therapeutics during the third quarter worth about $28,000. Russell Investments Group Ltd. acquired a new position in Palvella Therapeutics during the third quarter valued at approximately $36,000. China Universal Asset Management Co. Ltd. bought a new position in Palvella Therapeutics in the fourth quarter valued at approximately $167,000. Finally, The Manufacturers Life Insurance Company bought a new position in Palvella Therapeutics in the fourth quarter valued at approximately $238,000. Institutional investors own 40.11% of the company’s stock.

About Palvella Therapeutics

Palvella Therapeutics, Inc (NASDAQ: PVLA) is a clinical‐stage biopharmaceutical company devoted to the discovery and development of innovative therapies for immunological and inflammatory diseases. The company employs a proprietary small‐molecule and biologics platform to identify and modulate key molecular pathways that drive neutrophil‐ and complement‐mediated inflammation, aiming to deliver targeted treatment options for patients with significant unmet medical needs.

Palvella’s pipeline comprises several preclinical assets designed to address both prevalent chronic inflammatory conditions and rare autoinflammatory syndromes.